Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Horizon Therapeutics Denmark ApS
APS
Dissolved
CVR 43478060
Sundkrogsgade 21
Business and other management consultancy activities · NACE 7020
Est. 2022
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 0
EBITDA margin
—
Equity ratio
89.1%
Financial strength
Net profit 2024
DKK 500
+102% vs 2023
EBITDA — year on year
DKK millions
0M
-0M
-1M
-1M
-1M
0M
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
DKK 0
—
EBITDA
DKK 0
—
Net profit
DKK 500
+102%
Total assets
DKK 46K
+14%
Equity
DKK 41K
+292%
Employees
—
—
Company information
Legal name
Horizon Therapeutics Denmark ApS
CVR number
43478060
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
25. august 2022
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem eller af den samlede bestyrelse .
Contact
Address
Sundkrogsgade 21
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Business and other management consultancy activities
Companies in København
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
Income statement
DKK thousands
Item
2023
2024
Revenue
-30
0
Staff expenses
-0
-0
EBITDA
-30
0
Depreciation & amort.
-0
-0
EBIT
-30
0
Net financials
0
1
Profit before tax
-30
1
Tax
-0
-0
Net profit
-30
1
Balance sheet
DKK thousands
Item
2023
2024
Total assets
40
46
Equity
10
41
Long-term debt
30
0
Short-term debt
0
5
Total debt
30
5
Financial ratios
5-year trend
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
2023
2024
Equity ratio
89.1%
This company
38.2%
Market median
+133% vs market
2023
2024
Return on equity
1.2%
This company
18.4%
Market median
-93% vs market
2023
2024
Net profit margin
50000.0%
This company
8.1%
Market median
+617184% vs market
2023
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2023
2024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-08-25 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Former (2)
KL
Karin Louise Ulrika Järperud
Management
Management
2023 – 2025
PF
Paraskevi Florou
Management
Management
2023 – 2025
Board of directors
Non-executive oversight
Name
Role
Member since
Former (4)
WD
William David Gannon
Board of Directors
2022 – 2023
DJ
David James Caraher
Board of Directors
2022 – 2023
Tv
Tore von Würden Petersen
Chairman
2023 – 2025
PP
Patrick Paul McIlvenny
Chairman
2022 – 2023
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Horizon Therapeutics Ireland DAC
Individual
100%
100%
2022
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Horizon Therapeutics Denmark ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Karin Louise Ulrika Järperud
Management
0 companies
Paraskevi Florou
Management
0 companies
William David Gannon
Board of Directors
0 companies
David James Caraher
Board of Directors
0 companies
Tore von Würden Petersen
Chairman
0 companies
Patrick Paul McIlvenny
Chairman
0 companies